Scarica l'app Stockscreener
167.74
0.72%
1.20
Dopo l'orario di chiusura:
168.00
0.26
+0.16%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$166.54
Aprire:
$166.68
Volume 24 ore:
121.98K
Relative Volume:
0.59
Capitalizzazione di mercato:
$3.29B
Reddito:
$152.42M
Utile/perdita netta:
$45.24M
Rapporto P/E:
66.83
EPS:
2.51
Flusso di cassa netto:
$6.97M
1 W Prestazione:
+4.86%
1M Prestazione:
+23.89%
6M Prestazione:
+45.53%
1 anno Prestazione:
+63.55%
Intervallo 1D:
$166.49
$168.50
Intervallo di 1 settimana:
$160.05
$168.50
Portata 52W:
$93.58
$168.50
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Nome
Ligand Pharmaceuticals Inc
Settore
Industria
Telefono
858-550-7500
Indirizzo
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Confronta LGND con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
167.74 | 3.19B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
396.93 | 102.81B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.54 | 58.59B | 2.46B | -319.09M | -52.09M | -2.47 |
|
REGN
Regeneron Pharmaceuticals Inc
|
567.22 | 61.25B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ARGX
Argen X Se Adr
|
733.66 | 43.23B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
318.73 | 36.53B | 3.81B | -644.79M | -669.77M | -6.24 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-10 | Iniziato | Stifel | Buy |
| 2024-10-03 | Iniziato | Oppenheimer | Outperform |
| 2024-07-30 | Iniziato | RBC Capital Mkts | Outperform |
| 2021-04-14 | Ripresa | Stephens | Overweight |
| 2021-02-04 | Reiterato | H.C. Wainwright | Buy |
| 2020-10-06 | Iniziato | Barclays | Overweight |
| 2020-03-24 | Downgrade | Argus | Buy → Hold |
| 2020-03-10 | Iniziato | Guggenheim | Neutral |
| 2020-02-06 | Iniziato | The Benchmark Company | Buy |
| 2019-09-19 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Iniziato | Barclays | Equal Weight |
| 2019-05-03 | Reiterato | H.C. Wainwright | Buy |
| 2019-03-06 | Reiterato | H.C. Wainwright | Buy |
| 2018-10-29 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Reiterato | H.C. Wainwright | Buy |
| 2018-09-11 | Reiterato | Argus | Buy |
| 2018-08-17 | Iniziato | Goldman | Neutral |
| 2018-08-08 | Downgrade | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Iniziato | Argus | Buy |
| 2017-12-27 | Reiterato | H.C. Wainwright | Buy |
| 2017-09-05 | Ripresa | H.C. Wainwright | Buy |
| 2016-10-05 | Reiterato | H.C. Wainwright | Buy |
| 2016-08-05 | Downgrade | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Iniziato | Sidoti | Buy |
| 2016-03-03 | Iniziato | H.C. Wainwright | Buy |
Mostra tutto
Ligand Pharmaceuticals Inc Borsa (LGND) Ultime notizie
Real time pattern detection on Ligand Pharmaceuticals Incorporated stockWeekly Market Outlook & Accurate Technical Buy Alerts - Newser
Is Ligand Pharmaceuticals Incorporated stock bottoming outJuly 2025 News Drivers & AI Based Buy/Sell Signal Reports - Newser
Advanced analytics toolkit walkthrough for Ligand Pharmaceuticals IncorporatedQuarterly Investment Review & High Conviction Investment Ideas - Newser
Using flow based indicators on Ligand Pharmaceuticals IncorporatedWeekly Profit Analysis & Free Daily Entry Point Trade Alerts - Newser
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $190 From $167, Maintains Outperform Rating - MarketScreener
Is Ligand Pharmaceuticals Incorporated stock poised for growthMarket Growth Review & Capital Protection Trading Alerts - Newser
Can volume confirm reversal in Ligand Pharmaceuticals Incorporated2025 Support & Resistance & Verified Short-Term Trading Plans - Newser
Custom strategy builders for tracking Ligand Pharmaceuticals IncorporatedJuly 2025 Volume & Comprehensive Market Scan Reports - Newser
Will earnings trigger a reversal in Ligand Pharmaceuticals Incorporated2025 Price Action Summary & Consistent Profit Focused Trading Strategies - Newser
Using data models to predict Ligand Pharmaceuticals Incorporated stock movement2025 Trading Volume Trends & Safe Entry Trade Reports - Newser
Aug Levels: What is the next catalyst for Ligand Pharmaceuticals IncorporatedQuarterly Market Summary & Risk Adjusted Buy/Sell Alerts - khodrobank.com
How to build a dashboard for Ligand Pharmaceuticals Incorporated stockTrade Analysis Summary & Safe Swing Trade Setups - Newser
Is this a good reentry point in Ligand Pharmaceuticals Incorporated2025 Support & Resistance & Low Risk High Reward Trade Ideas - Newser
Benchmark Reaffirms Buy Rating on Ligand with Raised PT to $175. - AInvest
Volume spikes in Ligand Pharmaceuticals Incorporated stock – what they meanMarket Performance Report & Capital Protection Trading Alerts - Newser
Applying Wyckoff theory to Ligand Pharmaceuticals Incorporated stockMarket Rally & Weekly Market Pulse Updates - Newser
Is Ligand Pharmaceuticals Incorporated attractive for institutional investorsLong Setup & Short-Term Trading Opportunity Alerts - khodrobank.com
Aug Movers: What is Ligand Pharmaceuticals Incorporated s revenue forecastJuly 2025 Catalysts & Weekly Breakout Watchlists - khodrobank.com
Will Ligand Pharmaceuticals Incorporated outperform the market in YEARTrade Entry Report & Smart Allocation Stock Reports - khodrobank.com
Will Ligand Pharmaceuticals Incorporated continue its uptrend2025 Institutional Moves & Accurate Trade Setup Notifications - Newser
Can Ligand Pharmaceuticals Incorporated rally from current levelsProduct Launch & Short-Term Trading Opportunity Alerts - Newser
Heatmap analysis for Ligand Pharmaceuticals Incorporated and competitorsJuly 2025 Snapshot & Capital Efficient Trading Techniques - Newser
Will Ligand Pharmaceuticals Incorporated see short term momentumMarket Rally & Growth Oriented Trade Recommendations - Newser
Using portfolio simulators with Ligand Pharmaceuticals Incorporated includedGDP Growth & Safe Capital Growth Plans - Newser
What to do if you’re stuck in Ligand Pharmaceuticals IncorporatedMarket Risk Analysis & Real-Time Stock Entry Alerts - Newser
Can Ligand Pharmaceuticals Incorporated recover in the next quarter2025 Market WrapUp & High Accuracy Trade Signal Alerts - Newser
Custom watchlist performance reports with Ligand Pharmaceuticals IncorporatedTrade Volume Summary & Fast Exit Strategy with Risk Control - Newser
How to manage a losing position in Ligand Pharmaceuticals IncorporatedTrade Entry Report & High Conviction Trade Alerts - Newser
Ligand Pharmaceuticals Incorporated stock chart pattern explainedWeekly Stock Recap & Weekly High Return Forecasts - Newser
Ligand Pharmaceuticals Inc Azioni (LGND) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Ligand Pharmaceuticals Inc Azioni (LGND) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| KOZARICH JOHN W | Director |
Aug 01 '25 |
Sale |
131.88 |
467 |
61,586 |
45,989 |
1.75%
1.11%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):